G. Wilson
About
G. Wilson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, G. Wilson has authored 34 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in G. Wilson's work include Colorectal Cancer Treatments and Studies (17 papers), Cancer Treatment and Pharmacology (8 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). G. Wilson is often cited by papers focused on Colorectal Cancer Treatments and Studies (17 papers), Cancer Treatment and Pharmacology (8 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). G. Wilson collaborates with scholars based in United Kingdom, United States and Germany. G. Wilson's co-authors include Marc Peeters, Timothy Price, Andrés Cervantes, Yevhen Hotko, Thierry André, Michel Ducreux, Florian Lordick, Cornelis J.A. Punt, Alberto Sobrero and Tudor–Eliade Ciuleanu and has published in prestigious journals such as Journal of Clinical Oncology, Critical Care Medicine and British Journal of Cancer.
In The Last Decade
G. Wilson
34 papers receiving 1.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| G. Wilson United Kingdom | 16 | 1.5k | 749 | 344 | 326 | 309 | 34 | 1.9k | ||
| Nobuyuki Mizunuma Japan | 23 | 1.5k 1.0× | 530 0.7× | 259 0.8× | 231 0.7× | 327 1.1× | 133 | 2.0k | ||
| Cees J. van Groeningen Netherlands | 15 | 1.3k 0.9× | 547 0.7× | 236 0.7× | 339 1.0× | 327 1.1× | 29 | 1.7k | ||
| Roger Faroux France | 23 | 1.7k 1.1× | 684 0.9× | 599 1.7× | 249 0.8× | 363 1.2× | 98 | 2.5k | ||
| Veronica Lonati Italy | 22 | 1.3k 0.8× | 656 0.9× | 384 1.1× | 307 0.9× | 134 0.4× | 42 | 1.8k | ||
| Mario Barugel Argentina | 13 | 1.5k 1.0× | 695 0.9× | 398 1.2× | 416 1.3× | 408 1.3× | 29 | 1.8k | ||
| Marine Gilabert France | 22 | 910 0.6× | 422 0.6× | 276 0.8× | 231 0.7× | 485 1.6× | 73 | 1.8k | ||
| Guy A. Van Hazel Australia | 18 | 1.9k 1.2× | 913 1.2× | 357 1.0× | 373 1.1× | 909 2.9× | 40 | 2.4k | ||
| Yihebali Chi China | 16 | 1.5k 1.0× | 817 1.1× | 378 1.1× | 238 0.7× | 203 0.7× | 67 | 2.0k | ||
| Cristina Grávalos Spain | 23 | 1.7k 1.1× | 960 1.3× | 426 1.2× | 300 0.9× | 165 0.5× | 81 | 2.3k | ||
| Massimo Lopez Italy | 21 | 1.6k 1.1× | 598 0.8× | 282 0.8× | 213 0.7× | 274 0.9× | 59 | 2.2k |
Countries citing papers authored by G. Wilson
Since
Specialization
Citations
This map shows the geographic impact of G. Wilson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Wilson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Wilson more than expected).
Fields of papers citing papers by G. Wilson
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by G. Wilson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Wilson. The network helps show where G. Wilson may publish in the future.
Co-authorship network of co-authors of G. Wilson
This figure shows the co-authorship network connecting the top 25 collaborators of G. Wilson. A scholar is included among the top collaborators of G. Wilson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Wilson. G. Wilson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Sunny, Nixon, et al.. (2024). A comparative techno-economic assessment of blue, green, and hybrid ammonia production in the United States. Sustainable Energy & Fuels. 8(7). 1495–1508.
2.
Mulcahy, Mary F., Riad Salem, Armeen Mahvash, et al.. (2021). LBA21 Radioembolization with chemotherapy for colorectal liver metastases: A randomized, open-label, international, multicenter, phase III trial (EPOCH study). Annals of Oncology. 32. S1295–S1295.
3.
Starnes, Sandra L., et al.. (2021). Predictors of clinical outcomes in patients undergoing curative treatment for esophageal or gastroesophageal junction adenocarcinoma.. Journal of Clinical Oncology. 39(15_suppl). e16067–e16067.
4.
Barriuso, Jorge, Alexandra Ferrera, Michael Braun, et al.. (2020). P-339 Real-world data (RWD) of the use of trifluridine/tipiracil hydrochloride (TFT) in patients with metastatic colorectal cancer: The Greater Manchester experience. Annals of Oncology. 31. S200–S200.
5.
Armstrong, Anne, et al.. (2019). The incidence of metastases detected on a staging CT scan prior to neoadjuvant chemotherapy in early stage breast cancer. Annals of Oncology. 30. iii35–iii36.
6.
Loncaster, J., Anne Armstrong, Sacha J. Howell, et al.. (2017). Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK. European Journal of Surgical Oncology. 43(5). 931–937.
7.
Fusco, Francesco, Jane Wolstenholme, Alastair Gray, et al.. (2017). Selective Internal Radiotherapy (SIRT) in Metastatic Colorectal Cancer Patients with Liver Metastases: Preliminary Primary Care Resource Use and Utility Results from The Foxfire Randomised Controlled Trial. Value in Health. 20(9). A445–A446.
8.
Saunders, Christobel, Michael Braun, G. Wilson, et al.. (2017). Rapid Analysis of Outcomes Using the Systemic Anti-Cancer Therapy (SACT) Dataset. Clinical Oncology. 29(7). e134–e136.
9.
Gray, Alastair, Jane Wolstenholme, Francesco Fusco, et al.. (2017). Quality of life in patients with liver metastases from colorectal cancer treated with first-line selective internal radiotherapy (SIRT): Results from the FOXFIRE prospective randomized studies. Annals of Oncology. 28. v201–v201.
10.
Armstrong, Anne, Andrew Wardley, G. Wilson, et al.. (2015). A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition. European Journal of Cancer. 51(18). 2725–2731.
11.
Peeters, Marc, Kelly S. Oliner, Timothy Price, et al.. (2014). KRAS/NRAS and BRAF Mutations in the 20050181 Study of Panitumumab + FOLFIRI for the 2ND-Line Treatment of Metastatic Colorectal Cancer: Updated Analysis. Annals of Oncology. 25. ii5–ii5.
12.
Peeters, Marc, Timothy Price, Andrés Cervantes, et al.. (2013). Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer. Annals of Oncology. 25(1). 107–116.
13.
Minckwitz, Gϋnter von, Miguel Martín, G. Wilson, et al.. (2012). Optimizing taxane use in MBC in the emerging era of targeted chemotherapy. Critical Reviews in Oncology/Hematology. 85(3). 315–331.
14.
Corrie, Pippa, Charles B. Wilson, Simon Bond, et al.. (2012). A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. British Journal of Cancer. 107(4). 585–587.
15.
Peeters, Marc, Timothy Price, Andrés Cervantes, et al.. (2010). Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 28(31). 4706–4713.
16.
Valle, Juan W., et al.. (2008). Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer. British Journal of Cancer. 99(4). 577–583.
17.
Valle, Juan W., et al.. (2007). Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a Phase I study. British Journal of Cancer. 96(1). 38–43.
18.
Valle, Juan W., et al.. (2007). Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (LV) (SCOUT) in patients with advanced colorectal cancer (ACRC): A phase I/II study. Journal of Clinical Oncology. 25(18_suppl). 4084–4084.
19.
Wilson, G., Angela Cramer, Arkadiusz Welman, et al.. (2006). Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. British Journal of Cancer. 95(10). 1410–1414.
20.
Chester, John, et al.. (2000). Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. Annals of Oncology. 11(2). 235–237.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Nobuyuki Mizunuma Breakdown of academic impact, for papers by Cees J. van Groeningen Breakdown of academic impact, for papers by Roger Faroux Breakdown of academic impact, for papers by Veronica Lonati Breakdown of academic impact, for papers by Mario Barugel Breakdown of academic impact, for papers by Marine Gilabert Breakdown of academic impact, for papers by Guy A. Van Hazel Breakdown of academic impact, for papers by Yihebali Chi Breakdown of academic impact, for papers by Cristina Grávalos Breakdown of academic impact, for papers by Massimo Lopez